Loading…
← CockpitCompetitor Analysis › 214450.KS PharmaResearch Co., Ltd.Open in the cockpit ↗

PharmaResearch Co., Ltd.214450.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major

Korean biotech known for PDRN-based Rejuran skin-booster injectables, alongside a pharmaceutical and cosmetic-ingredient business.

Momentum neutral 52
Mkt cap
$2.10B
US dollars, full cap
Free float
54%
of shares outstanding
$/day
$16.6M
20-day average traded
Fwd P/E
15.4×
forward earnings
ROIC−WACC
+26.0 pp
WACC 5.5%
Hurdle
-49 pp
Req g minus delivered
Next earnings
114 days
12 Mar 2027
Close · KRW₩265,000
1D+2.7%
1W+7.1%
1M-0.4%
3M-33.4%
6M-24.5%
YTD-34.2%
1Y-46.4%
ATR %6.1%
52w lowhigh52.8% off high

What PharmaResearch does

Korean biotech known for PDRN-based Rejuran skin-booster injectables, alongside a pharmaceutical and cosmetic-ingredient business.

Sells Rejuran to aesthetic clinics, which buy it for injection on their patients, with a growing part exported through local distributors; the older pharmaceutical line (Placentex) and PDRN supply to cosmetics makers give income beyond the clinics. Because the same core ingredient is used across all lines, patent protection and regulatory approvals in each country matter.

Products and services

  • Rejuran (PDRN skin boosters)
  • Cosmetic ingredient (PDRN) supply
  • Pharmaceutical products

Customers

  • Dermatology/aesthetic clinics (Korea, global)
  • Cosmetics brands (ingredient supply)

Where it sits in the supply chain

  • Biotech/cosmeceuticals
  • PDRN regenerative skincare and pharma
  • Aesthetic-clinic and…

What could go right

  • Global skin-booster export growth

What could go wrong

  • Regulatory/registration risk in new markets
  • Aesthetic-trend dependency

Moat: narrow (IP / patents, brand). Patented PDRN regenerative technology behind the globally popular Rejuran skin-booster brand.

Headquarters: Seongnam, South Korea · Founded: 2000 · Employees: 526

Named competitors

PharmaResearch at a glance

Size PharmaResearch (214450.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $2.10B, the 134th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩265,000 on 18 Nov 2026.

Performance Over six months the shares fell 24.5%, against +2.8% for the median peer and -37.2% for the South Korea market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue grew 29.0% over the last twelve months (peer median +10.7%); the operating margin is 37.1% (peer median 14.7%).

Valuation It trades at 15.4× forward earnings against a peer median of 25.2× (6th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +38%, so the hurdle is -49 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 26.0 points above its cost of capital (5.5% WACC).

Next results Next results expected around 12 Mar 2027 (exchange calendar; dates can move).

Relative performance

7510012521 May 202621 Aug 202618 Nov 2026Peer median 102214450.KS 81
Six months, rebased to 100: PharmaResearch against the median of its 20 peers (local-currency closes).

PharmaResearch financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩640B₩536B₩350B₩261B₩195B
Revenue growth—+53%+34%+34%—
Gross profit₩480B₩402B₩242B₩182B₩134B
EBITDA₩255B₩228B₩140B₩104B₩76.7B
Net income₩167B₩165B₩92.0B₩76.6B₩40.6B
Free cash flow₩105B₩154B₩102B₩52.9B₩42.2B
Capital expenditure₩52.3B₩35.8B₩38.7B₩13.2B₩17.8B
Total debt₩240B₩214B₩209B₩34.3B₩66.8B

Quarterly statements and history in the cockpit →

PharmaResearch competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%0%+20%H02688428600285603707603456300436600267600867APLLTD009420ERIS603858BHVNONESOURCEHRMY60020145400512SHILPAMED301080214450.KS6-month return →1-month return →
Up and to the right = strong over both horizons. PharmaResearch is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%25×50×75×H02688428600285603707600267ERISONESOURCEHRMY6002014540SHILPAMED301080214450.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. PharmaResearch is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%H02688428600285APLLTD301080214450.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. PharmaResearch is the large dot.

PharmaResearch competitors and peer comparison

Head to head with its named competitors (214450.KS vs 145020.KS vs 214150.KS vs 214370.KS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
PharmaResearch 214450.KS$2.10B-24%+29%37%15.4×-11.0%
Hugel 145020.KS$1.69B-30%+17%38%18.1×-12.1%
CLASSYS 214150.KS$1.08B-60%+16%43%13.7×-9.2%
Caregen 214370.KS$982M-74%-2%20%21.5×36.8%

How PharmaResearch compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

PharmaResearch against its 20 peers (data as of 18 Nov 2026)
Measure214450.KSPeer medianRank in peer set
1-month return-0.4%-0.9%11th highest of 21
6-month return-24.5%+2.8%4th lowest of 21
Distance from 52-week high-52.8%-26.1%2nd lowest of 21
Revenue growth (TTM)+29.0%+10.7%4th highest of 20
Operating margin37.1%14.7%highest of 19
Forward P/E15.4×25.2×6th cheapest of 17
Growth the price implies (Req g, 7 yrs)-11.0%1.5%least demanding of 15
Growth delivered (Del g)+37.6%+12.3%3rd highest of 15
Hurdle (Req g minus delivered)-48.6 pp-4.7 pp3rd least demanding of 15
ROIC minus cost of capital+26.0 pp-1.1 pphighest of 19
EV / EBITDA9.9×16.6×4th cheapest of 9
Net debt / EBITDA-1.2×1.2×3rd least indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
PharmaResearch 214450.KSSouth Korea$2.10B-24%+29%37%15.4×-11.0%+37.6%
Haw Par H02.SISingapore$2.08B-25%-13%30%11.9×3.2%+15.7%
InnoCare Pharma 688428.SSChina$2.07B-7%+135%35%85.7×-10.9%+344.2%
Henan Lingrui Pharmaceutial 600285.SSChina$2.04B+9%+5%22%15.9×-4.7%+10.6%
Nanjing King-friend Biochemical Pharmaceutical 603707.SSChina$2.03B-3%+9%14%25.9×5.1%+6.4%
Zhejiang Jiuzhou Pharmaceutical 603456.SSChina$2.03B+19%-1%14%16.9×1.7%+15.7%
Fujian Cosunter Pharmaceutical 300436.SZChina$2.02B-45%0%-47%n/an/an/a
Zhejiang Hisun Pharmaceutical 600267.SSChina$2.19B+14%-7%15%15.0×-9.7%-1.5%
Tonghua Dongbao Pharmaceutical 600867.SSChina$2.19B-12%+18%n/a25.4×0.9%+0.3%
Alembic Pharmaceuticals APLLTD.NSIndia$2.20B+39%+20%12%25.0×26.7%+6.5%
Hanall Biopharma 009420.KSSouth Korea$2.01B+12%+5%3%n/an/an/a
Eris Lifesciences ERIS.NSIndia$1.98B0%+11%26%27.9×26.3%+20.9%
Shandong Buchang Pharmaceuticals 603858.SSChina$2.25B-7%+4%10%n/a-2.5%-5.8%
Biohaven BHVNUnited States$1.95B+46%n/an/an/an/an/a
OneSource Specialty Pharma ONESOURCE.NSIndia$1.95B-14%+11%6%44.6×n/an/a
Harmony Biosciences HRMYUnited States$1.94B+6%+20%22%8.6×-10.5%+40.3%
Jinyu Bio-Technology 600201.SSChina$1.93B-21%+22%10%59.0×23.4%-2.5%
Tsumura & 4540.TJapan$1.93B+6%+13%18%10.4×n/an/a
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%9.4×1.2%+14.1%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%54.3×n/an/a
Acrobiosystems 301080.SZChina$2.31B+65%+29%17%55.2×41.3%+27.7%

Questions

Who are PharmaResearch's main competitors?
Named competitors: Hugel (145020.KS), CLASSYS (214150.KS), Caregen (214370.KS). The cockpit's measured peer set (industry) also includes Haw Par (H02.SI), InnoCare Pharma (688428.SS), Henan Lingrui Pharmaceutial (600285.SS), Nanjing King-friend Biochemical Pharmaceutical (603707.SS), Zhejiang Jiuzhou Pharmaceutical (603456.SS), Fujian Cosunter Pharmaceutical (300436.SZ).
Is PharmaResearch expensive compared with its peers?
On forward p/e it trades at 15.4× against a peer median of 25.2×, 6th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +38%, so the hurdle is -49 pp: the price already allows for a slowdown.
How has PharmaResearch stock performed?
Over six months to 18 Nov 2026 the shares returned -24.5% against +2.8% for the median peer; over one year -46.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.